5-Amino-1MQ

What 5-Amino-1MQ Does

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of NNMT — nicotinamide N-methyltransferase — an enzyme that has emerged as a significant target in obesity and metabolic research. Despite being sold by peptide suppliers and discussed within the peptide community, 5-Amino-1MQ is not a peptide. It is a quinolinium salt — a small organic molecule with a molecular weight of approximately 175 Da. For context, BPC-157 is 1,419 Da and insulin is 5,808 Da. This distinction matters because it explains why 5-Amino-1MQ can be taken orally (small molecules survive digestion; peptides do not).

The mechanisms that matter:

• NNMT inhibition — NNMT is an enzyme that methylates nicotinamide (vitamin B3) using SAM (S-adenosylmethionine) as the methyl donor. This reaction produces 1-methylnicotinamide (1-MNA) and SAH (S-adenosylhomocysteine). In obese individuals, NNMT is overexpressed in white adipose tissue — up to 2-3x higher than in lean individuals. This overexpression diverts nicotinamide away from NAD+ synthesis and depletes the cellular SAM pool. 5-Amino-1MQ blocks this enzyme, restoring normal metabolic flux
• NAD+ preservation — by preventing NNMT from consuming nicotinamide, more nicotinamide remains available for recycling into NAD+ via the salvage pathway (NAMPT enzyme). Higher cellular NAD+ levels support mitochondrial function, sirtuin activity (SIRT1-7), and overall energy metabolism. This connects 5-Amino-1MQ mechanistically to the broader NAD+/longevity research field
• SAM conservation — SAM is the universal methyl donor for hundreds of cellular methylation reactions, including DNA methylation (epigenetic regulation), neurotransmitter synthesis, and phospholipid production. NNMT overexpression in obesity depletes SAM. NNMT inhibition preserves SAM for these essential processes
• Adipocyte metabolism — in cell culture and animal studies, NNMT inhibition reduced adipocyte (fat cell) size, decreased lipogenesis (new fat creation), and increased energy expenditure. The effect appears specific to white adipose tissue where NNMT is most highly expressed
• Potential anti-fibrotic effects — NNMT is also overexpressed in fibrotic tissues. Some research suggests NNMT inhibition could reduce tissue fibrosis, though this is secondary to the metabolic application

Why NNMT Matters in Obesity

The NNMT-obesity connection was established through genomic and metabolomic studies that identified NNMT as one of the most significantly upregulated enzymes in adipose tissue of obese humans:

1. Obese adipose tissue overexpresses NNMT — creating a metabolic sink that drains both nicotinamide (needed for NAD+) and SAM (needed for methylation)
2. NAD+ depletion in fat cells — lower NAD+ means less sirtuin activity, less mitochondrial function, less fat oxidation. Fat cells become metabolically sluggish
3. SAM depletion — reduced methylation capacity may contribute to the epigenetic changes observed in obesity
4. Vicious cycle — metabolically sluggish fat cells store more fat, further increasing NNMT expression

5-Amino-1MQ breaks this cycle by inhibiting the enzyme at the center of it. The appeal is obvious: rather than forcing weight loss through appetite suppression (GLP-1 drugs) or direct lipolysis (AOD-9604), NNMT inhibition addresses a root metabolic dysfunction in adipose tissue.

The NAD+ Connection

5-Amino-1MQ’s mechanism connects directly to the broader NAD+ longevity field. By inhibiting NNMT, the compound prevents nicotinamide from being methylated and wasted — instead preserving it for the NAD+ salvage pathway. The salvage pathway is the primary route by which cells recycle nicotinamide back into NAD+ via the enzyme NAMPT (nicotinamide phosphoribosyltransferase).

This means 5-Amino-1MQ and direct NAD+ precursors (NMN, NR) are mechanistically complementary:

• NMN/NR — provide additional raw material for NAD+ synthesis
• 5-Amino-1MQ — prevents the loss of existing nicotinamide that would otherwise be methylated away by NNMT

Some practitioners combine oral NMN (500-1,000 mg/day) with 5-Amino-1MQ (100 mg/day) as a dual-pronged NAD+ strategy — boosting supply while reducing waste. This combination is theoretically sound but has zero clinical validation.

SAM and Epigenetic Implications

The SAM-sparing effect of NNMT inhibition has implications beyond fat metabolism. SAM (S-adenosylmethionine) is the universal methyl donor for:

• DNA methylation — the epigenetic marks that silence or activate genes
• Histone methylation — chromatin modification that controls gene accessibility
• Neurotransmitter synthesis — dopamine, serotonin, norepinephrine, and melatonin all require methylation steps
• Phospholipid synthesis — cell membrane integrity depends on SAM-dependent methylation

In obesity, NNMT overexpression depletes the SAM pool. This methyl donor depletion may contribute to the epigenetic dysregulation observed in metabolic syndrome — altered gene expression patterns that perpetuate the obese phenotype. NNMT inhibition could theoretically help restore normal methylation patterns. This is speculative but represents a genuinely novel therapeutic angle.

5-Amino-1MQ vs Other Fat Loss Compounds

Feature	5-Amino-1MQ	Semaglutide	AOD-9604
Type	Small molecule	Peptide (GLP-1 agonist)	Peptide (HGH fragment)
Mechanism	NNMT inhibition (metabolic)	Appetite suppression (central)	Lipolysis stimulation (peripheral)
Route	Oral	Injection (weekly)	Injection (daily)
Weight loss magnitude	Modest (limited human data)	15-17% body weight	Modest (2-3 kg fat in trials)
Human trial data	None published	Extensive (STEP trials)	Limited (Phase 2)
FDA status	Not approved, not regulated	FDA-approved (Ozempic/Wegovy)	Not FDA-approved
Appetite effects	None directly	Strong suppression	None
Best use case	Metabolic optimization, adjunct	Primary weight loss	Targeted fat loss, refinement

Dosing Protocol

Standard Protocol

Parameter	Detail
Dose	50–150 mg/day
Frequency	Once daily (oral)
Route	Oral capsule
Duration	8–12 weeks
Best timing	Morning, with or without food

Dose Tiers

Dose	Use Case
50 mg/day	Starting dose — assess tolerance and response
100 mg/day	Standard dose — most common protocol
150 mg/day	Upper range — used by some practitioners for enhanced effect

Start at 50 mg/day for the first week, then increase to 100 mg/day if well-tolerated. Some users increase to 150 mg/day after 2-4 weeks at 100 mg, though the marginal benefit of the higher dose is unestablished in human data. The dose-response relationship in humans is unknown — animal study doses do not translate directly.

Timing Guidance

• Morning dosing — take with breakfast or on an empty stomach. No established requirement for fasting vs fed state
• Consistent daily timing — same time each day for stable levels
• No injection preparation — this is the primary practical advantage. Open capsule, swallow, done
• Can be combined with other morning supplements — no known interactions with common supplements (multivitamins, fish oil, creatine)

No Reconstitution Needed

5-Amino-1MQ comes as pre-made oral capsules from compounding pharmacies and research suppliers. No reconstitution, no bacteriostatic water, no syringes. This is the simplest protocol in the peptide community in terms of administration.

Storage: Store capsules at room temperature in a cool, dry place. No refrigeration required. Protect from moisture and direct sunlight. Shelf life is typically 12-18 months from manufacture date.

Cycling

Protocol	On Period	Off Period	Rationale
Standard	8 weeks	4 weeks	Conservative approach; assess response
Extended	12 weeks	4 weeks	Longer exposure for more metabolic impact
Maintenance	Ongoing	No off period	Some practitioners use continuously (limited safety data for this approach)

Cycling is recommended primarily because long-term human safety data does not exist. The 8-12 week on, 4 week off pattern allows:

1. Assessment of individual response during the on-period
2. Monitoring for any delayed side effects during the off-period
3. Evaluation of whether benefits persist after discontinuation

Unlike GLP-1 drugs (where discontinuation leads to appetite rebound and weight regain), 5-Amino-1MQ’s metabolic effects may partially persist after stopping — if the metabolic improvements in adipose tissue are sustained. This is speculative and unconfirmed in humans.

What to Expect

Week 1 (50 mg/day)

• No noticeable effects for most users
• NNMT inhibition is beginning at the cellular level, but metabolic changes take time to manifest
• Assess tolerance — GI comfort, energy levels, sleep quality
• This is the trial period before dose escalation

Weeks 2-4 (100 mg/day)

• Some users report subtle energy improvements — attributed to increased cellular NAD+ availability
• No significant body composition changes yet
• Appetite is unaffected (5-Amino-1MQ does not suppress appetite)
• If training and nutrition are dialed in, recovery quality may subtly improve

Weeks 4-8

• Body composition changes may become measurable — slight reduction in body fat percentage with stable lean mass
• The effect is gradual and subtle — not a dramatic transformation
• Users who are already lean (sub-15% body fat) may notice more visible changes than those with significant weight to lose (where the effect is proportionally smaller)
• Energy levels and metabolic “feel” may improve — users describe feeling more metabolically efficient during exercise

Weeks 8-12

• Cumulative metabolic effects peak
• Total fat loss over 12 weeks: user reports suggest 2-5 lbs in the context of caloric deficit and exercise
• Effects are most apparent in combination with structured training and moderate caloric restriction
• Without a concurrent caloric deficit, body composition changes are minimal — 5-Amino-1MQ improves metabolic efficiency but does not override energy balance

Post-Cycle

• Some metabolic benefits may persist — the NAD+ and SAM pool improvements may maintain for weeks after stopping
• No withdrawal effects or rebound weight gain reported (unlike GLP-1 drugs)
• Fat loss achieved during the cycle is maintained to the extent that diet and exercise habits persist

What the Research Says

5-Amino-1MQ has a growing but still early-stage research base. There are no published human clinical trials. All evidence comes from preclinical studies and mechanistic work.

NNMT as an obesity target (Kraus et al., 2014, Nature): This seminal paper identified NNMT as highly upregulated in white adipose tissue and liver of obese mice and demonstrated that NNMT knockdown (using antisense oligonucleotides) reduced adiposity and improved glucose homeostasis. NNMT-knockdown mice on a high-fat diet gained significantly less weight and fat mass than controls. The paper established NNMT as a legitimate therapeutic target for metabolic disease. Published in Nature.

5-Amino-1MQ in diet-induced obese mice (Neelakantan et al., 2018, Biochemical Pharmacology): This study directly tested 5-Amino-1MQ in a mouse obesity model. Treatment with the NNMT inhibitor for 10 days reduced body weight and total fat mass in diet-induced obese mice without affecting food intake. The compound also reduced adipocyte size and lowered plasma total cholesterol. Importantly, the fat loss occurred without appetite suppression — confirming a metabolic mechanism distinct from GLP-1 drugs. Published in Biochemical Pharmacology.

NNMT in human adipose tissue (Kannt et al., 2015, PLOS ONE): This study confirmed that NNMT expression is significantly elevated in adipose tissue of obese humans compared to lean controls, and that NNMT expression correlates with insulin resistance. Weight loss (via bariatric surgery) reduced NNMT expression. This translational data supports the relevance of the mouse findings to human obesity.

NNMT and the NAD+/SAM metabolic hub (Ulanovskaya et al., 2013, Nature Chemical Biology): Demonstrated that NNMT sits at a critical metabolic junction — regulating the balance between NAD+ synthesis (energy metabolism) and SAM-dependent methylation (epigenetic regulation). NNMT overexpression in cancer and obesity disrupts both pathways simultaneously. Published in Nature Chemical Biology.

NNMT inhibitors in cancer (various studies): NNMT is also overexpressed in several cancers (bladder, gastric, pancreatic). NNMT inhibition has shown anti-tumor effects in cell culture models. This is a secondary research direction but highlights the enzyme’s broad biological significance.

Key context:

• No human clinical trials of 5-Amino-1MQ have been published as of early 2026. The compound exists in a preclinical evidence stage
• The mechanistic rationale is strong (NNMT overexpression in obesity is well-documented), but translation from mouse models to human clinical outcomes is unproven
• Derek (More Plates More Dates) has covered 5-Amino-1MQ, noting the intriguing mechanism but cautioning about the complete absence of human trial data
• The compound’s popularity in the peptide community is driven more by mechanistic appeal and the convenience of oral dosing than by proven clinical outcomes

Safety

Side Effects

Side Effect	Frequency	Notes
GI discomfort	~5-10% (user reports)	Mild; nausea or stomach upset in some users
Headache	~5% (user reports)	Usually first few days, self-limiting
Insomnia	~3% (user reports)	Possible if taken late in the day; morning dosing recommended

No formal human safety data exists. The side effect frequencies above are estimated from user reports in online peptide communities — not from controlled trials. The absence of reported serious side effects is encouraging but does not constitute a safety profile.

Critical Warnings

No human clinical trial data. This is the overriding safety concern. 5-Amino-1MQ has not been tested in controlled human trials for safety, efficacy, or pharmacokinetics. You are operating without any of the safety infrastructure that exists for approved or even investigational drugs.

NNMT has functions beyond fat metabolism. NNMT is expressed in the liver, brain, and other tissues — not just adipose tissue. Systemic NNMT inhibition could have effects on:

• Hepatic drug metabolism (NNMT metabolizes some xenobiotics)
• Neurotransmitter metabolism (nicotinamide methylation products affect neurological pathways)
• One-carbon metabolism (SAM conservation affects global methylation patterns)

Long-term consequences of chronic NNMT inhibition in humans are unknown.

Drug interactions are unstudied. NNMT metabolizes several compounds, and inhibiting it could alter the clearance of co-administered drugs. If you take prescription medications, discuss 5-Amino-1MQ with your physician — though most physicians will be unfamiliar with the compound.

Product quality concerns. Because 5-Amino-1MQ is not an FDA-regulated product, quality varies between suppliers. The compound is relatively simple to synthesize (small molecule), but purity, dose accuracy, and contamination are not guaranteed. Demand certificates of analysis with HPLC purity data.

This is not a first-line fat loss intervention. For meaningful weight loss, evidence-based options (GLP-1 agonists, caloric restriction, exercise) should be prioritized. 5-Amino-1MQ is an experimental adjunct for metabolic optimization — not a primary treatment.

Do Not Use If

• Pregnant or breastfeeding (no safety data)
• Under 18 (metabolic development should not be pharmacologically altered)
• Active liver disease (NNMT is hepatically expressed; inhibition effects unknown)
• Taking medications metabolized by NNMT (consult physician)
• History of cancer (NNMT’s role in cancer biology is complex and incompletely understood)

What Comes Next

• Evidence-based fat loss — Semaglutide Protocol for the most proven pharmacological weight loss approach
• Complementary fat loss — AOD-9604 Protocol for a mechanistically different (lipolysis-based) approach
• Read the comparison — Weight Loss Peptides Compared for a side-by-side of all options
• Metabolic foundation — MOTS-c Protocol for mitochondrial function and exercise mimetic benefits